PLoS ONE (Jan 2022)

Impact of early detection on cancer curability: A modified Delphi panel study.

  • Lee Schwartzberg,
  • Michael S Broder,
  • Sikander Ailawadhi,
  • Himisha Beltran,
  • L Johnetta Blakely,
  • G Thomas Budd,
  • Laurie Carr,
  • Michael Cecchini,
  • Patrick Cobb,
  • Anuraag Kansal,
  • Ashley Kim,
  • Bradley J Monk,
  • Deborah J Wong,
  • Cynthia Campos,
  • Irina Yermilov

DOI
https://doi.org/10.1371/journal.pone.0279227
Journal volume & issue
Vol. 17, no. 12
p. e0279227

Abstract

Read online

Expert consensus on the potential benefits of early cancer detection does not exist for most cancer types. We convened 10 practicing oncologists using a RAND/UCLA modified Delphi panel to evaluate which of 20 solid tumors, representing >40 American Joint Committee on Cancer (AJCC)-identified cancer types and 80% of total cancer incidence, would receive potential clinical benefits from early detection. Pre-meeting, experts estimated how long cancers take to progress and rated the current curability and benefit (improvement in curability) of an annual hypothetical multi-cancer screening blood test. Post-meeting, experts rerated all questions. Cancers had varying estimates of the potential benefit of early cancer detection depending on estimates of their curability and progression by stage. Cancers rated as progressing quickly and being curable in earlier stages (stomach, esophagus, lung, urothelial tract, melanoma, ovary, sarcoma, bladder, cervix, breast, colon/rectum, kidney, uterus, anus, head and neck) were estimated to be most likely to benefit from a hypothetical screening blood test. Cancer types rated as progressing quickly but having comparatively lower cure rates in earlier stages (liver/intrahepatic bile duct, gallbladder, pancreas) were estimated to have medium likelihood of benefit from a hypothetical screening blood test. Cancer types rated as progressing more slowly and having higher curability regardless of stage (prostate, thyroid) were estimated to have limited likelihood of benefit from a hypothetical screening blood test. The panel concluded most solid tumors have a likelihood of benefit from early detection. Even among difficult-to-treat cancers (e.g., pancreas, liver/intrahepatic bile duct, gallbladder), early-stage detection was believed to be beneficial. Based on the panel consensus, broad coverage of cancers by screening blood tests would deliver the greatest potential benefits to patients.